We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 92.12%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
76
Cartesian Therapeutics
RNAC
$218M
$2.52M 0.02%
5,857
– –
JNCE
77
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.2M 0.02%
+100,000
New +$2.12M
DMTX
78
DELISTED
Dimension Therapeutics, Inc
DMTX
$2.19M 0.02%
1,251,881
– –
TNXP icon
79
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
CBIO
80
Crescent Biopharma
CBIO
$546M
$2.07M 0.02%
3,812
– –
NTRA icon
81
Natera
NTRA
$36.4B
$2.03M 0.02%
228,676
-20,593
-8% -$196K
FSTX
82
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.95M 0.02%
54,825
– –
INFI
83
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.88M 0.02%
580,400
– –
NVIV
84
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$1.62M 0.01%
21
– –
MDWD icon
85
MediWound
MDWD
$184M
$1.49M 0.01%
32,286
– –
SYRE icon
86
Spyre Therapeutics
SYRE
$8.5B
$1.42M 0.01%
7,599
-8,570
-53% -$1.21M
MCRB icon
87
Seres Therapeutics
MCRB
$45M
$1.41M 0.01%
6,250
– –
FLGT icon
88
Fulgent Genetics
FLGT
$558M
$1.36M 0.01%
125,000
– –
MYOK
89
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.31M 0.01%
100,000
– –
CLLS
90
Cellectis
CLLS
$288M
$1.2M 0.01%
50,000
– –
JUNO
91
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.11M 0.01%
50,000
-30,000
-38% -$643K
CRBP icon
92
Corbus Pharmaceuticals
CRBP
$165M
$1.07M 0.01%
4,338
-4,333
-50% -$1.06M
IMDZ
93
DELISTED
Immune Design Corp.
IMDZ
$1.01M 0.01%
148,937
– –
AFMD
94
DELISTED
Affimed
AFMD
$920K 0.01%
40,000
– –
MDGL icon
95
Madrigal Pharmaceuticals
MDGL
$12.6B
$890K 0.01%
57,762
– –
XLRN
96
DELISTED
Acceleron Pharma
XLRN
$761K 0.01%
28,765
– –
CMRX
97
DELISTED
Chimerix, Inc.
CMRX
$735K 0.01%
115,216
– –
FPRX
98
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$696K 0.01%
19,247
– –
PTN
99
Palatin Technologies
PTN
$14.4M
$671K 0.01%
1,640
– –
ABUS icon
100
Arbutus Biopharma
ABUS
$847M
$587K ﹤0.01%
180,582
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Baker Bros. Advisors held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Baker Bros. Advisors's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Baker Bros. Advisors added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Baker Bros. Advisors's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Baker Bros. Advisors fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Baker Bros. Advisors opened 4 new positions and closed 18 in Q1 2017.
  • Baker Bros. Advisors's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.